Envista Holdings Corporation (NVST)
NVSTNYSEMedical/Dental Instruments
$25.84
-0.1300 (-0.50%) today
At the close, Nov 10, 4:00 PM ET. After hours $25.84 +0.43%
- Market cap
- $4.13bn
- P/E
- 16.7
- EPS, last 4 quarters
- $1.55
- Dividend yield
- –
- Day range
- $25.29 to $26.02
- 52-week range
- $18.77 to $30.42
- Average volume
- 1.67m
- Previous close
- $25.97
Analysts
14 coveringHold7 buy, 7 hold, 0 sell
Targets a year out average $29.45, +14.0% from here
Earnings
next estimate $0.3900Next report
Dec 2025
+18.8%
Mar 2026
+16.1%
Jun 2026
+24.2%
Sep 2026
+14.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Apr 2026 | Jul 2026 | Oct 2026 |
|---|---|---|---|---|
| Revenue | $750.60m | $705.50m | $730.50m | $691.50m |
| Gross profit | $410.60m | $390.10m | $407.00m | $400.60m |
| Operating income | $73.30m | $62.50m | $80.30m | $515.20m |
| Net income | $32.90m | $38.70m | $53.70m | $508.30m |
Last four quarters: revenue $2.88bn, margin 22.0%, free cash flow $242.00m
News
8 latest- Envista (NVST) is a Top-Ranked Momentum Stock: Should You Buy?Zacks · 4 days ago
- Envista Q3 Earnings Call Highlights '26 Guidance Raise & China RisksZacks · 5 days ago
- Envista (NVST) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Envista (NVST) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Envista (NVST) Reports Q3 Earnings: What Key Metrics Have to SayZacks · 6 days ago
- Envista (NVST) Tops Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Envista Q3 Earnings Ahead: Product Innovation to Drive GrowthZacks · Oct 28, 2026
- Envista (NVST) Earnings Expected to Grow: Should You Buy?Zacks · Oct 28, 2026
The company
Envista is a global leader in the dental industry, uniting more than 30 trusted brands-including DEXIS, Kerr, Nobel Biocare, and Ormco-under one mission: partnering with dental professionals to improve patients' lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care-today and for the future.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NYSE
- Region
- North America
- Website
- envistaco.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.